Anticoagulants do not directly affect platelet aggregation but help mitigate thrombotic microangiopathies by reducing clot formation, aiding in preventing organ damage.

Anticoagulants mainly prevent new clot formation rather than impacting existing platelet aggregation, crucial in managing thrombotic microangiopathies to reduce complications.

In thrombotic microangiopathies, anticoagulants indirectly aid by reducing thrombin, decreasing further platelet activation and clots, which is essential for patient stability and recovery.